Cytosin-Arabinosid
Myelodysplastic Syndrome/Acute Myeloid Leukemia
National Cancer Institute (NCI)Phase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Myelodysplastic Syndrome/Acute Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Azacitidine City of Hope Medical Center | Phase 2/3 | BB |
Decitabine National Cancer Institute (NCI) | Phase 2/3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2/3 | B |
Midostaurin National Cancer Institute (NCI) | Phase 2/3 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →